NCT04058847

Brief Summary

Under 50% of patients diagnosed with hypertension and treated in general practice, have reached a blood pressure within the recommended levels of the national guideline. Compliance is the main problem for these patients, but effective tools for increasing patient compliance are missing. The objective is to evaluate the risk-assessment and risk-communication tool: "Your Heart Forecast", to see if it can improve patient compliance, health literacy and empowerment. Patients will be followed in a cluster-randomised controlled trial in the setting of general practice, using surveys at inclusion and after 6 and 12 months. Besides surveys, the participants' blood pressure will be measured as a hard outcome and data will be drawn from various patient databases. After 6 months, qualitative interviews will be conducted, with a subgroup of patients from the intervention group. It is expected to find whether the use of Your Heart Forecast can lower patients' blood pressure and/or increase their compliance, health literacy and empowerment. The aim is to show if an increase in general health literacy and patient empowerment, as measured by Patient Activation Measure(PAM13) can be seen. The investigators hope to reveal whether this software can improve patient compliance and thereby be a reasonable tool to implement in the national blood pressure control program. In further studies, it should be shown if the cost of using this program is far less than expenses for hospitalisation due to complications and comorbidity to hypertension.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
600

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Mar 2019

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 26, 2018

Completed
5 months until next milestone

Study Start

First participant enrolled

March 27, 2019

Completed
5 months until next milestone

First Posted

Study publicly available on registry

August 16, 2019

Completed
3.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2022

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2022

Completed
Last Updated

May 23, 2022

Status Verified

May 1, 2022

Enrollment Period

3.5 years

First QC Date

October 26, 2018

Last Update Submit

May 20, 2022

Conditions

Keywords

Risk communicationCVD-riskGeneral practicePrimary careVisual communicationInteractive communicationCardiovascular risk

Outcome Measures

Primary Outcomes (1)

  • Health literacy

    Self-reported change in health literacy through questionnaires.

    Questionnaire sent out at inclusion, after 6 months and after 1 year

Secondary Outcomes (4)

  • Blood pressure

    Calculated after the 1 year trial period

  • Adherence

    Questionnaire sent out at inclusion, after 6 months and after 1 year

  • Empowerment

    Questionnaire sent out at inclusion, after 6 months and after 1 year

  • Number of contacts

    Counted after end of 1 year trial period.

Study Arms (2)

Intervention

EXPERIMENTAL

Use of Your Heart Forecast and an e-mail follow up-program.

Other: Your Heart Forecast

Control

NO INTERVENTION

The control group uses standard regime (business as usual).

Interventions

1 year follow up with Your Heart Forecast and a follow-up email every 2 weeks.

Intervention

Eligibility Criteria

Age35 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • All patients must understand and read Danish and must be cognitively well functioning.
  • The patient must have Internet access, host an email address and read their emails on regular basis (at least once a week).
  • All included patients must be diagnosed with hypertension and go to regular blood pressure control consultations at their GP (at least once a year).
  • Both patients with known hypertension and those newly discovered are accepted into the trial.
  • Age from 35 to 75 years (both included).
  • Both genders are included.

You may not qualify if:

  • If the patient during the trial develops prolonged illness so severe that treatment of hypertension is no longer a priority, he/she will be excluded.
  • Patients with blood pressure above 170/100 are excluded, as these patients should receive intensive blood pressure treatment regardless of their predicted CVD risk or heart age.
  • Pregnancy.
  • Very high cholesterol (TCL or TCL/HDL 8 or over).
  • Genetic lipid disorders.
  • If the patient is diabetic AND has a complicating kidney disease.
  • Known problems with arteries to the legs defined as:
  • Clinical symptoms of claudication
  • Diminished foot pulses
  • Carotid bruits
  • Radiological evidence
  • Prior surgery /percutaneous interventions
  • Prior stroke or mini-stroke (TIA).
  • Angina, prior AMI or heart related operation.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Research Unit of General Practice, Department of Public Health, University of Southern Denmark

Odense, Region Syddanmark, 5000, Denmark

Location

Related Publications (14)

  • Reuther LO, Paulsen MS, Andersen M, Schultz-Larsen P, Christensen HR, Munck A, Larsen PV, Damsgaard J, Poulsen L, Hansen DG, Christensen B, Sondergaard J. Is a targeted intensive intervention effective for improvements in hypertension control? A randomized controlled trial. Fam Pract. 2012 Dec;29(6):626-32. doi: 10.1093/fampra/cms031. Epub 2012 May 7.

    PMID: 22565110BACKGROUND
  • Soureti A, Hurling R, Murray P, van Mechelen W, Cobain M. Evaluation of a cardiovascular disease risk assessment tool for the promotion of healthier lifestyles. Eur J Cardiovasc Prev Rehabil. 2010 Oct;17(5):519-23. doi: 10.1097/HJR.0b013e328337ccd3.

    PMID: 20195154BACKGROUND
  • Pedersen KM, Andersen JS, Sondergaard J. General practice and primary health care in Denmark. J Am Board Fam Med. 2012 Mar;25 Suppl 1:S34-8. doi: 10.3122/jabfm.2012.02.110216.

    PMID: 22403249BACKGROUND
  • Brust-Renck PG, Royer CE, Reyna VF. Communicating Numerical Risk: Human Factors That Aid Understanding in Health Care. Rev Hum Factors Ergon. 2013 Oct;8(1):235-276. doi: 10.1177/1557234X13492980.

    PMID: 24999307BACKGROUND
  • Berkman ND, Sheridan SL, Donahue KE, Halpern DJ, Crotty K. Low health literacy and health outcomes: an updated systematic review. Ann Intern Med. 2011 Jul 19;155(2):97-107. doi: 10.7326/0003-4819-155-2-201107190-00005.

    PMID: 21768583BACKGROUND
  • Wells S, Kerr A, Eadie S, Wiltshire C, Jackson R. 'Your Heart Forecast': a new approach for describing and communicating cardiovascular risk? Heart. 2010 May;96(9):708-13. doi: 10.1136/hrt.2009.191320. No abstract available.

    PMID: 20424153BACKGROUND
  • De Geest S, Sabate E. Adherence to long-term therapies: evidence for action. Eur J Cardiovasc Nurs. 2003 Dec;2(4):323. doi: 10.1016/S1474-5151(03)00091-4. No abstract available.

    PMID: 14667488BACKGROUND
  • Maindal HT, Sokolowski I, Vedsted P. Translation, adaptation and validation of the American short form Patient Activation Measure (PAM13) in a Danish version. BMC Public Health. 2009 Jun 29;9:209. doi: 10.1186/1471-2458-9-209.

    PMID: 19563630BACKGROUND
  • Sorensen K, Pelikan JM, Rothlin F, Ganahl K, Slonska Z, Doyle G, Fullam J, Kondilis B, Agrafiotis D, Uiters E, Falcon M, Mensing M, Tchamov K, van den Broucke S, Brand H; HLS-EU Consortium. Health literacy in Europe: comparative results of the European health literacy survey (HLS-EU). Eur J Public Health. 2015 Dec;25(6):1053-8. doi: 10.1093/eurpub/ckv043. Epub 2015 Apr 5.

    PMID: 25843827BACKGROUND
  • Perestelo-Perez L, Rivero-Santana A, Boronat M, Sanchez-Afonso JA, Perez-Ramos J, Montori VM, Serrano-Aguilar P. Effect of the statin choice encounter decision aid in Spanish patients with type 2 diabetes: A randomized trial. Patient Educ Couns. 2016 Feb;99(2):295-9. doi: 10.1016/j.pec.2015.08.032. Epub 2015 Sep 1.

    PMID: 26343571BACKGROUND
  • Prochaska JO, Velicer WF. The transtheoretical model of health behavior change. Am J Health Promot. 1997 Sep-Oct;12(1):38-48. doi: 10.4278/0890-1171-12.1.38.

    PMID: 10170434BACKGROUND
  • Madsbad S, Larsen ML, Adeler HF, Kryhlmand M, Westergaard M. [Implementation of clinical guidelines in general practice. The effect of journal audit and continuing education for the treatment of cardiovascular risk factors in patients with and without type 2 diabetes]. Ugeskr Laeger. 2006 Apr 24;168(17):1640-5. Danish.

    PMID: 16674875BACKGROUND
  • Stjernholm K, Andersen HS, Jensen AE, Nielsen JB. Danish evaluation of Your Heart Forecast: a cluster randomised controlled trial aimed at improving modifiable risk factors of CVD. Open Heart. 2026 Jan 28;13(1):e003812. doi: 10.1136/openhrt-2025-003812.

  • Jensen AE, Sondergaard J, Kjaer NK, Jackson R, Nielsen JB. Danish Evaluation of Your Heart Forecast (DANY): study protocol for a cluster randomised controlled trial on an interactive risk-communication tool aimed at improving adherence of patients with high blood pressure. Trials. 2020 Jan 3;21(1):11. doi: 10.1186/s13063-019-3886-2.

Study Officials

  • Jesper B Nielsen, Professor, PhD

    Research Unit of General Practice, University of Southern Denmark

    STUDY CHAIR
  • Anders E Jensen, M.D.

    Research Unit of General Practice, University of Southern Denmark

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Model Details: Cluster-randomised clinical trial with 1 year follow up. The general practitioners are randomised into an intervention group and a control group. Participants automatically follow their general practitioner into the allocated group.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Medical doctor, Principal Investigator

Study Record Dates

First Submitted

October 26, 2018

First Posted

August 16, 2019

Study Start

March 27, 2019

Primary Completion

October 1, 2022

Study Completion

December 31, 2022

Last Updated

May 23, 2022

Record last verified: 2022-05

Data Sharing

IPD Sharing
Will not share

Data from the project is only intended to be shared by publishing anonymised results.

Locations